News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 28/10/2026 +03			Pre-market 15:24:52
57.29 ^USD	+28.25%		56.50	-1.38%

12:46pm	Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy	FW
11:25am	Genmab: Positive developments priced in; time to take profits

All News

Mentions Relevance

12:46pm	Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy	FW
11:25am	Genmab: Positive developments priced in; time to take profits
10:48am	SEB raises price target for Genmab to DKK 4,600 (3,175), reiterates buy	FW
10:47am	DNB Carnegie downgrades Genmab to hold (buy), target price DKK 4,100 (3,100)	FW
10:06am	Jyske Bank cuts Genmab to sell (hold), price target DKK 3,725 - BN	FW
09:29am	Nordea raises price target for Genmab to 4,500 Danish kroner (3,200), reiterates Buy	FW
08:44am	Sydbank lowers Genmab to hold (buy) - BN	FW
07:38am	TD Cowen raises price target for Genmab to DKK 4,526 (3,435), reiterates buy - LSEG	FW
07:02am	Barclays raises price target for Genmab to 4,500 Danish kroner (3,400), reiterates overweight	FW
10-28	Genmab A/S - Special Call
10-28	Genmab Reports Positive Results for Petosemtamab Combination in Late-stage Head & Neck Cancer Trial	MT
10-28	Genmab surges after clinical success in head and neck cancer
10-28	Genmab Says Phase 3 Trial of Petosemtamab Combination Meets Both Primary Endpoints; Shares Rise	MT
10-28	Genmab reaches key milestones in Phase 3 study, shares jump	FW
10-28	Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer	BU
10-28	Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer	GL
10-28	Genmab Announces Statistically Significant Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination At First Interim Analysis in First-Line Recurrent or Metastatic Patients with Pd-L1 Positive Head and Neck Cancer	CI
10-28	AlphaValue/Baader Europe Downgrades Genmab to Reduce	MT
10-26	Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma	CI
10-26	Deutsche Bank raises price target for Genmab to 3,500 Danish kroner (3,000), reiterates buy	FW
10-26	Genmab Reports 28.2-Month Median Survival in Petosemtamab Combination Trial	MT
10-26	Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	BU
10-26	Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	GL
10-26	Jefferies raises target price for Genmab, boosts view on oncology portfolio	FW
10-26	Genmab surges 13% on promising cancer data	FW